Filing Flows

Filing Flows › Health Care › Abbott Laboratories (ABT)

Abbott Laboratories (ABT) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Abbott Laboratories (ABT) Q3 2026 earnings results →

Q3 2026 Revenue up 14% year over year to $13.0B · 7¢ of every $1 of revenue kept as net profit · operating margin 10.4%

Abbott Laboratories made $13.0B in Q3 2026 (+14% Y/Y). Operating margin 10.4%, net earnings $920M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$13.0B
Year over year+14%
Operating margin10.4%
Net earnings$920M
Operating cash flow$1.7B

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Abbott Laboratories Q3 2026 revenue breakdown: Sankey diagram of revenue, costs, profit and cash flow
Abbott Laboratories Q3 2026 revenue breakdown — free to use with credit and a link (terms). Share on X
Embed this chart on your site

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Revenue was $13.0B in Q3 2026, up 14% year over year and up 3% from the previous quarter.

Operating profit was $1.4B, a 10.4% margin (down 7.7 points year over year). Operating profit fell $0.70B even though revenue rose $1.6B versus Q3 2025, so costs grew faster than sales. Total costs grew 25% against revenue growth of 14%. The fastest-growing cost line was Other operating costs (+100%). Net earnings were $0.92B, down 44% year over year. The effective tax rate was 25.3%.

Operating cash flow was $1.7B (down 38% year over year), 189% of net earnings. Non-cash charges added back $1.3B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items used $0.58B. Capital expenditures of $0.51B left free cash flow of $1.2B.

Quarterly history

Abbott Laboratories revenue by quarterAbbott Laboratories revenue by quarter$10.4BQ1 2025$11.1BQ2 2025$11.4BQ3 2025$11.5BQ4 2025$11.2BQ1 2026$12.6BQ2 2026$13.0BQ3 2026
Abbott Laboratories net earnings by quarterAbbott Laboratories net earnings by quarter$1.3BQ1 2025$1.8BQ2 2025$1.6BQ3 2025$1.8BQ4 2025$1.1BQ1 2026$928MQ2 2026$920MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 4, 2026$13.0B+14%10.4%$920M$1.7B
Q2 202610-QJul 28, 2026$12.6B+13%13.4%$928M$2.5B
Q1 202610-QApr 29, 2026$11.2B+8%12.0%$1.1B$1.3B
Q4 202510-KFeb 20, 2026$11.5B+4%19.6%$1.8B$3.3B
Q3 202510-QOct 29, 2025$11.4B+7%18.1%$1.6B$2.8B
Q2 202510-QJul 30, 2025$11.1B+7%18.4%$1.8B$2.0B
Q1 202510-QApr 30, 2025$10.4B+4%16.3%$1.3B$1.4B

Charts

Abbott Laboratories: revenue growth, year over year and quarter over quarterAbbott Laboratories: revenue growth, year over year and quarter over quarterY/YQ/Q+4%Q1 2025+7%+8%Q2 2025+7%+2%Q3 2025+4%+1%Q4 2025+8%-3%Q1 2026+13%+13%Q2 2026+14%+3%Q3 2026
Latest (Q3 2026): Y/Y +14%, Q/Q +3%.
Abbott Laboratories: where the cash came from (+) and went (−), TTM to Q3 2026Abbott Laboratories: where the cash came from (+) and went (−), TTM to Q3 2026Other investing−$20.2BOther financing$15.7BOperating cash flow$8.9BDividends−$4.3BCash drawn (+) / kept (−)$3.5BCapital spending−$2.1BBuybacks−$1.5BShares issued$224MNet borrowing (+) / repaid (−)−$45.0MExchange rates−$12.0M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Abbott Laboratories: profit against cash, quarter by quarterAbbott Laboratories: profit against cash, quarter by quarterNet incomeOperating cash flow$9.2B$2.9BQ4 2024$1.3B$1.4BQ1 2025$1.8B$2.0BQ2 2025$1.6B$2.8BQ3 2025$1.8B$3.3BQ4 2025$1.1B$1.3BQ1 2026$928M$2.5BQ2 2026$920M$1.7BQ3 2026
Latest (Q3 2026): Net income $920M, Operating cash flow $1.7B.
Abbott Laboratories: diluted shares by fiscal yearAbbott Laboratories: diluted shares by fiscal year1.79BFY20201.79BFY20211.76BFY20221.75BFY20231.75BFY20241.75BFY2025
-2.1% since FY2020: buybacks shrank the count.
Abbott Laboratories: long-term debt falling due (FY2025)Abbott Laboratories: long-term debt falling due (FY2025)$3.0B2026$700M2027$653M2028$591M2029$650M2030$7.4BLater
Cash $8.5B, short-term investments $417M, long-term debt $12.9B at 2025-12-31.
Abbott Laboratories in its industry: growth against margin (225 companies, SIC 2834)Abbott Laboratories in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMABT (+14%, 10%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Sells to

Buys from

About Abbott Laboratories

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.

In its own words, from its 10-K, filed Feb 20, 2026.

Abbott Laboratories against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +14% against the peers' median +7%. Operating margin: 10.4% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%
TEVA Teva Pharmaceutical IndustriesQ3 2026$4.4B-2%16.2%

Source: Abbott Laboratories 10-Q on SEC EDGAR · CIK 1800 · Pharmaceutical Preparations

Guidance and outlook

Abbott Laboratories: what its forward-looking statements are about (10-K filed 2026-02-20)Abbott Laboratories: what its forward-looking statements are about (10-K filed 2026-02-20)Demand3
3 statements; tone -0.33 (−1 all cautious, +1 all confident); 0 hedged.
Abbott Laboratories: outlook statements against the filing beforeAbbott Laboratories: outlook statements against the filing beforeCautious1

13F: who owns ABT and who is buying

Largest holders of ABT (13F)Largest holders of ABT (13F)Vanguard Group$22.0BBlackRock$13.8BVanguard Capital Management LLC$10.3BState Street$7.3BCharles Schwab Investment Managem…$5.4BVanguard Portfolio Management LLC$4.4BGeode Capital Management, LLC$3.5BCapital Research Global Investors$3.3BCapital International Investors$3.1BMorgan Stanley$2.4B
Funds' net buying of ABT by quarter (13F)Funds' net buying of ABT by quarter (13F)−$3.3B2024-09$63.0M2024-12$1.5B2025-03$1.3B2025-06$635M2025-09$9.8B2025-12−$5.2B2026-03−$1.1B2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ABT

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare ABT with

中文版：雅培（ABT）财报

Español · Français